bioMérieux and Moderna Collaborate to Advance Individualized Cancer Therapies

Strategic Insights -

As the two companies embark on a decade-long partnership, they are leveraging diagnostic innovations to accelerate the development of personalized cancer treatments. From its inception in 2017, the collaboration has evolved into a comprehensive diagnostic partnership, with bioMérieux's BACT/ALERT systems and VITEK MS for microbial identification supporting Moderna's oncology pipeline. This partnership not only exemplifies the potential of innovation and collaboration in advancing scientific breakthroughs but also has a tangible impact on public health and patient outcomes worldwide.

Key Takeaways:

  • The partnership between bioMérieux and Moderna began in 2017 with the installation of BACT systems at Moderna's Cambridge site.
  • The collaboration has since expanded to include BACT/ALERT systems and VITEK MS for microbial identification.
  • The partnership has supported Moderna's Phase 3 trials in melanoma and non-small cell lung cancer.
  • bioMérieux's diagnostic innovations have also helped reduce batch release times and optimize sterility testing processes for Moderna.
  • The partnership is poised to support Moderna's global operations, including new sites in Australia, Canada, and the UK.
  • The two companies are working on implementing advanced automation and digital solutions to improve the delivery of individualized cancer therapies.

Statistics:

  • The partnership between bioMérieux and Moderna began in 2017.
  • Moderna is running Phase 3 trials in melanoma and non-small cell lung cancer.
  • bioMérieux's diagnostic innovations have helped reduce batch release times and optimize sterility testing processes for Moderna.
  • Moderna plans to expand its global operations to new sites in Australia, Canada, and the UK.
  • The partnership aims to support the delivery of individualized cancer therapies worldwide.

Sources:

  • bioMérieux Original Press Release, July 25, 2017